The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab
Authors
Mallardo, DWoodford, R
Menzies, AM
Zimmer, L
Williamson, Andrew
Ramelyte, E
Dimitriou, F
Wicky, A
Wallace, R
Mallardo, M
Cortellini, A
Budillon, A
Atkinson, V
Sandhu, S
Olivier, M
Dummer, R
Lorigan, Paul C
Schadendorf, D
Long, GV
Simeone, E
Ascierto, PA
Affiliation
Christie NHS Foundation Trust and Division of Cancer Services, University of Manchester, Manchester, UKIssue Date
2023
Metadata
Show full item recordAbstract
Background: The combination of nivolumab + relatlimab is superior to nivolumab alone in the treatment of naive patients and has activity in PD-1 refractory melanoma. We had previously observed a reduced expression of LAG3 in melanoma tissue from patients with type 2 diabetes. Method: To evaluate the impact of diabetes on oncological outcomes of patients with advanced melanoma treated with nivolumab plus the LAG3 inhibitor relatlimab we performed a retrospective multicenter study. Results: Overall, 129 patients were included: 88 without diabetes before the treatment, 37 who were diagnosed with type 2 diabetes before the start of treatment, and 4 without diabetes before treatment who developed immune checkpoint inhibitor-induced diabetes (ICI-DM). PFS was 21.71 months (95% CI: 15.61-27.81) in patients without diabetes, 10.23 months (95% CI: 5.81-14.66) in patients with type 2 diabetes, and 50.85 months (95% CI: 23.04-78.65) in patients who developed ICI-DM. OS was 37.94 months (95% CI: 31.02-44.85) in patients without diabetes, 22.12 months (95% CI: 14.41-29.85) in those with type 2 diabetes and 57.64 months (95% CI: 42.29-72.99) in those who developed ICI-DM. Multivariate analysis showed that the presence of diabetes and LDH was correlated with OS and PFS. The mean OS was 64.63 months in subjects with low levels of glucose (< 137 mg/dl) and 36.27 months in those with high levels (hazard ratio 0.16, 95% CI: 0.04-0.58; p = 0.005). The patients whose glucose blood level increased after 3 months of treatment with nivolumab + relatinib compared to baseline (ratio of blood level at baseline/after 3 months > 1.5) had a worse prognosis than those whose glucose level had not increased. This result was observed also in subgroups treated either in first line or further lines. Patients who developed ICI-DM during the study period had better outcomes than the overall population and patients without diabetes. Conclusions: LAG3 inhibition for treating metastatic or unresectable melanoma has a reduced efficacy in patients with type 2 diabetes, possibly due to a low expression of LAG3 in tumor tissue. Higher level evidence should be obtained.Citation
Mallardo D, Woodford R, Menzies AM, Zimmer L, Williamson A, Ramelyte E, et al. The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab. JOURNAL OF TRANSLATIONAL MEDICINE. 2023 OCT 25;21(1). PubMed PMID: WOS:001088915900005. English.Journal
Journal Of Translational MedicineDOI
10.1186/s12967-023-04607-4PubMed ID
37880788Type
Articleae974a485f413a2113503eed53cd6c53
10.1186/s12967-023-04607-4
Scopus Count
Collections
Related articles
- Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis.
- Authors: Boutros A, Tanda ET, Croce E, Catalano F, Ceppi M, Bruzzone M, Cecchi F, Arecco L, Fraguglia M, Pronzato P, Genova C, Del Mastro L, Lambertini M, Spagnolo F
- Issue date: 2023 Jul
- Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma.
- Authors: Long GV, Stephen Hodi F, Lipson EJ, Schadendorf D, Ascierto PA, Matamala L, Salman P, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, Janoski De Menezes J, Dalle S, Arance A, Grob JJ, Keidel S, Shaikh A, Sobiesk AM, Dolfi S, Tawbi HA
- Issue date: 2023 Apr
- Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
- Authors: Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV, RELATIVITY-047 Investigators
- Issue date: 2022 Jan 6
- MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG.
- Authors: Kreft S, Glutsch V, Zaremba A, Schummer P, Mohr P, Grimmelmann I, Gutzmer R, Meier F, Pföhler C, Sachse MM, Meiss F, Forschner A, Haferkamp S, Welzel J, Terheyden P, Herbst R, Utikal J, Kaatz M, Weishaupt C, Kreuter A, Debus D, Duecker P, Sindrilaru A, Löffler H, Schley G, Weichenthal M, Schadendorf D, Ugurel S, Gesierich A, Schilling B
- Issue date: 2022 May
- Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
- Authors: Jang SR, Nikita N, Banks J, Keith SW, Johnson JM, Wilson M, Lu-Yao G
- Issue date: 2021 Dec 1